Assessing the Climate Change Vulnerability of Ecosystem Types of the Southwestern U.S.

Climate change is challenging scientists and decision-makers to understand the complexities of climate change and to predict the related effects at scales relevant to environmental policy and the management of ecosystem services. Extraordinary change in climate, and the ensuing impacts to ecosystem services, are widely anticipated for the southwestern United States. Predicting the vulnerability of Southwest ecosystems and their components has been a priority of natural resource organizations over the past decade. Supplementing vulnerability assessments in the region with geospatial inputs of high thematic and spatial detail has become vital for supporting local analyses, planning, and decisions. In this context has come the opportunity to build upon a framework of major ecosystem types of the Southwest and to assess vulnerability to climate change for each type. Herein are presented three studies that set the backdrop for vulnerability assessment, detail a novel correlative modeling procedure to predict the location and the magnitude of vulnerability to familiar vegetation patterns, and then explore applications of the resulting geospatial vulnerability surface: 1) considerations for evaluating or designing a vulnerability assessment; 2) an overview of the vegetation and climate of major ecosystem types, and 3) a climate change vulnerability assessment for all major ecosystem types of the Southwest. This work has resulted in a regionwide vulnerability surface of greater extent and higher spatial and thematic resolution than previous modeling efforts, giving local managers information on the location and degree of climate risk to vegetation resources

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

Heteromorphisme floral chez <i>Dais cotinifolia</i> L. (<i>Thymelaeaceae</i>) : un cas possible d'hétérophyllie.

Un hétéromorphisme floral est signalé chez Dais cotinifolia L. (Thymelaeaceae), associé une suite inhabituelle de caractères secondaires. Les styles des fleurs apétales présentent trois morphologies différentes. Dans la forme style moyen, les étamines du verticille supérieur sont de longueurs moyennes plutôt que longues, comme celles d\u27autres espèces tristyles. La morphologie des papilles stigmatiques ainsi que l\u27ornementation du pollen varient entre les trois formes de style, mais la taille du pollen reste constante. Le périanthe de la forme style moyen est notamment plus court que chez les formes style long ou court. Cette suite inhabituelle de caractères dans une espèce apparemment tristyle élargit la gamme d\u27hétéromorphisme floral actuellement acceptée. Il est aussi évident qu\u27une étude plus complète est souhaitable pour les Thymelaeaceae tropicales (ainsi que pour l\u27ensemble des angiospermes tropicaux).Floral heteromorphism is reported in Dais cotinifolia L. (Thymelaeaceae) and is associated with an unusual array of ancillary features. The apetalous flowers have three different style morphologies. The upper whorl of stamens in the mid style morph are mid-length, instead of having a whorl of long stamens, as in other tristylous species. There are differences in the morphology of the stigmatic papillae and pollen sculpturing among the three style morphs, however, there is no difference in pollen size. The perianth in the mid style morph is significantly shorter than the perianth in the short and long style morphs. This unusual array of features in what appears to be a tristylous species suggest that floral heteromorphism may be more variable than previously thought. It is also apparent that a more complete survey of tropical Thymelaeaceae (and tropical angiosperms in general) for floral heteromorphism is needed

Shanghai Service Robot

A robotic base and control program capable of following a user was created that linked TwinCAT automation software, and Visual Studios C++. Microsoft’s Kinect sensor and Xbox Controller were used for communication between the robot and the user. The robot used skeletal gestures, speech recognition, and remote commands to accomplish task

Comparative Pollen Morphology of Brachylena, Tarchananthus and Two Species of Tubulifloridites (Asteraceae) From the Eocene, Knysna Lignite of South Africa

Two fossil taxa Tubulifloridites antipodica and T. viteauensis recovered from the Eocene Knysna Lignite of South Africa were examined with scanning (SEM) and transmission electron microscopy (TEM). The details of their sculpturing and wall structure are similar to the same species of fossil dispersed pollen taxa recovered from southwestern Africa and South America. Fifteen species of the woody South African taxa, Brachylaena (9 species) and Tarchonanthus (6 species) were investigated with SEM and TEM. All of the taxa are tricolporate, spherical to slightly prolate, microechinate to echinate and have a bilayered columellate infrastructure, except B. ilicifolia, which has a single columellate infrastructural level with the granularization of the outer portion of the infrastructural layer or the inner layer of the tectum. There is a similar distribution of plesiomorphic and derived pollen characters in a number of aster subfamilies and tribes suggesting a similar evolutionary progression of pollen, and pollen wall character evolution was occurring synchronously in a variety of aster subfamilies during the middle Tertiary and that these unique pollen features may be important to the evolution and diversification of the Asteraceae

Additions to the floras of Colorado and New Mexico

Volume: 79Start Page: 319End Page: 32

Leaf Anatomy of Orcuttieae (Poaceae: Chloridoideae): More Evidence of C 4 Photosynthesis without Kranz Anatomy

Volume: 55Start Page: 143End Page: 15

Sphaeromeria, a genus closer to Artemisia than to Tanacetum (Asteraceae: Anthemideae)

A new species,Sphaeromeria ruthiae, from Zion National Park, and three new combinations,S. martirensis,S. compacta, andS. potentilloides var.nitrophila, are presented. Morphological and anatomical evidence is used to support the recognition ofSphaeromeria as distinct fromTanacetum